Business Context and Reporting Period
This Form 8-K is a current report filed by Vivos Therapeutics, Inc. on June 15, 2022, regarding events occurring on June 14, 2022. The Company is an emerging growth company incorporated in Delaware with its principal executive offices in Littleton, Colorado. The filing primarily addresses a corporate event under Item 8.01 (Other Events).
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This report is a current event disclosure rather than a periodic financial statement.
Material Changes
The material change reported is the presentation of positive results from a retrospective study involving Vivos patients. This presentation occurred at SLEEP 2022, the annual meeting of the Associated Professional Sleep Societies, held on June 14, 2022.
Guidance, Outlook, and Management Commentary
Management highlighted the positive outcomes of the retrospective study presented at the SLEEP 2022 conference. The full details of the study and the associated press release are included as Exhibit 99.1. The filing does not contain updated financial guidance, specific risk factors, or contingencies beyond the standard disclosures for an emerging growth company.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated June 14, 2022) for specific clinical data and study methodology.
- Verify the Company's status as an emerging growth company and its implications for financial reporting standards.
- Confirm the trading symbol (VVOS) and exchange (NASDAQ) for current market data.
- Check subsequent filings for any financial impact or strategic shifts resulting from the study results.